A one-stop supplier for researchers working on everything from basic biology to drug discovery
In a move that echoes the rhythms of industrial consolidation, Germany's Merck KGaA has agreed to acquire Minneapolis-based Bio-Techne for $11.3 billion — its most consequential purchase in over a decade. The deal reflects a quiet but persistent truth about modern science: the tools that enable discovery are themselves becoming as valuable as the discoveries they produce. By absorbing a supplier of half a million laboratory products, Merck is not merely buying revenue; it is buying proximity to the entire ecosystem of research, from university benches to biotech pipelines.
- Merck KGaA is committing $11.3 billion to acquire Bio-Techne, its largest deal since the landmark Sigma-Aldrich purchase in 2015 — a signal that the company is done waiting on the sidelines of life sciences growth.
- Bio-Techne's catalog of roughly 500,000 reagents, instruments, and research supplies makes it a daily dependency for academic labs, pharmaceutical developers, and clinical diagnostics operations worldwide.
- The life sciences tools sector is consolidating rapidly, and smaller single-focus suppliers are increasingly vulnerable as customers gravitate toward integrated, one-stop providers.
- For Merck, the acquisition simultaneously adds revenue scale, deepens institutional relationships, and sends a competitive message that it intends to dominate the research infrastructure space.
- The deal awaits regulatory approval, after which Bio-Techne will fold into Merck's life sciences division while its Minneapolis operations are expected to remain intact.
Merck KGaA has announced plans to acquire Bio-Techne, a Minneapolis-based manufacturer of laboratory tools and research materials, in an $11.3 billion deal — the German company's largest since it purchased Sigma-Aldrich more than a decade ago. The acquisition signals a deliberate and aggressive push deeper into the life sciences infrastructure market, where demand has remained resilient even as other corners of the pharmaceutical industry face uncertainty.
Bio-Techne has built itself into an indispensable supplier, offering a catalog of roughly 500,000 products — reagents, instruments, and consumables — that researchers across academia, biotech, and clinical diagnostics depend on daily. That breadth made it a compelling target. For Merck, absorbing Bio-Techne means not just adding product lines, but embedding itself more deeply into the workflows of the institutions and companies driving modern science forward.
The move mirrors a wider pattern of consolidation reshaping the life sciences tools market. As customers increasingly seek integrated suppliers capable of meeting diverse needs under one roof, companies with expansive portfolios hold a structural advantage. Merck's 2015 Sigma-Aldrich acquisition established its credentials in this space; the Bio-Techne deal doubles down on that strategy.
Subject to regulatory approval, Bio-Techne will become part of Merck's life sciences division, with its Minneapolis headquarters expected to remain operational. For investors, the deal represents a clear wager: that the market for research tools and materials will continue outpacing much of the broader pharmaceutical landscape for years to come.
Merck KGaA, the German life sciences and pharmaceutical company, is spending $11.3 billion to acquire Bio-Techne, a Minneapolis-based manufacturer of laboratory tools and research materials. The deal, announced in June 2026, represents the largest acquisition Merck has made since it bought Sigma-Aldrich more than a decade ago, signaling an aggressive push into a sector where demand continues to climb.
Bio-Techne brings to the table a sprawling portfolio of roughly 500,000 products—reagents, instruments, and other supplies that researchers and diagnostic labs rely on every day. The company has built itself into a critical supplier for life sciences work, from academic research to pharmaceutical development to clinical diagnostics. For Merck, the acquisition is a way to deepen its presence in laboratory tools and reagents, areas where growth has remained steady even as other parts of the pharmaceutical industry face headwinds.
The last time Merck made a deal of comparable scale was in 2015, when it acquired Sigma-Aldrich for roughly the same amount of money. That purchase established Merck as a major player in the chemicals and lab supplies space. This new acquisition of Bio-Techne suggests the company sees continued opportunity in that same territory—and is willing to pay substantially to secure it.
The life sciences tools market has become increasingly valuable as research institutions, biotech companies, and diagnostic labs expand their operations. Bio-Techne's 500,000-product catalog positions it as a one-stop supplier for many of these customers, which likely made it an attractive target. The company serves researchers working on everything from basic biology to drug discovery to disease diagnostics.
For Merck, the deal accomplishes several things at once. It adds significant revenue and product breadth to the company's life sciences division. It gives Merck deeper relationships with research institutions and biotech firms that depend on reliable supplies of high-quality reagents and tools. And it signals to investors and competitors that Merck remains committed to growth in sectors where demand is expanding, even as it navigates the complexities of the broader pharmaceutical market.
The acquisition also reflects a broader trend in the life sciences industry: consolidation among suppliers of research tools and materials. As the market grows more sophisticated and customers demand integrated solutions, larger players with diverse product portfolios have advantages over smaller, single-focus competitors. By absorbing Bio-Techne, Merck is positioning itself to offer customers a wider range of products and services under one roof.
The deal is expected to close subject to customary regulatory approvals and closing conditions. Once complete, Bio-Techne will operate as part of Merck's life sciences division, though the company's Minneapolis headquarters and operations will likely remain in place. For Merck shareholders, the acquisition represents a bet that the life sciences tools market will continue to grow faster than many other segments of the pharmaceutical and chemical industries.
The Hearth Conversation Another angle on the story
Why does a German pharmaceutical company need to spend $11 billion on a Minneapolis lab-supplies maker? What's the strategic logic?
Life sciences tools are where steady, predictable growth lives right now. Merck already owns Sigma-Aldrich from 2015. This is them doubling down on the same bet—that researchers and biotech companies will keep needing more reagents, more instruments, more supplies as they scale up their work.
But couldn't Merck just build this capability themselves, or acquire smaller companies more cheaply?
They could, but Bio-Techne brings 500,000 products already in the catalog, plus customer relationships that took decades to build. You're not just buying inventory—you're buying trust. Labs don't switch suppliers lightly.
Is this about defending market share, or about growth?
Both. The life sciences tools market is growing. If Merck doesn't consolidate now, a competitor will. And consolidation itself creates value—you can eliminate redundancies, cross-sell products, offer integrated solutions that smaller players can't match.
What happens to Bio-Techne's employees and operations?
The company will likely stay in Minneapolis and operate as part of Merck's life sciences division. That's the pattern with these deals—you keep the talent and the local operations intact because they're part of what you paid for.
Who wins and who loses from this deal?
Merck wins access to growth. Bio-Techne shareholders win a premium price. Customers might eventually win if Merck can offer better integrated solutions. The real question is whether smaller competitors in lab supplies can survive in a market where the big players keep getting bigger.